Advertisement
Canada markets close in 3 hours 8 minutes

  • S&P/TSX

    21,815.03
    -196.69 (-0.89%)
     

  • S&P 500

    5,049.64
    -20.91 (-0.41%)
     

  • DOW

    38,333.20
    -170.49 (-0.44%)
     

  • CAD/USD

    0.7290
    -0.0030 (-0.42%)
     

  • CRUDE OIL

    82.63
    -0.73 (-0.88%)
     

  • Bitcoin CAD

    88,736.00
    -2,873.62 (-3.14%)
     

  • CMC Crypto 200

    1,394.95
    -29.15 (-2.05%)
     

  • GOLD FUTURES

    2,338.50
    -3.60 (-0.15%)
     

  • RUSSELL 2000

    1,983.80
    -18.84 (-0.94%)
     

  • 10-Yr Bond

    4.6480
    +0.0500 (+1.09%)
     

  • NASDAQ

    15,650.33
    -46.31 (-0.30%)
     

  • VOLATILITY

    16.30
    +0.61 (+3.89%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6818
    -0.0018 (-0.26%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference

Replimune Group Inc
·1 min read

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 7:30 AM ET.

A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference.

About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform has a unique dual local and systemic mechanism of action (MOA) consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment (TME) to ignite a strong and durable systemic response. This MOA is expected to be synergistic with most established and experimental cancer treatment modalities, and, with an attractive safety profile the RPx platform has the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Lissette Steele
Verge Scientific Communications
202.930.4762 x 409
lsteele@vergescientific.com